* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UJ9 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Shandong Boan Biotechnology Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Boan Biotechnology Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shandong Boan Biotechnology Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Shandong Boan Biotechnology Co's Days Payable falls into.
Shandong Boan Biotechnology Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Boan Biotechnology Co (FRA:UJ9) has a Days Payable of 293.74 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shandong Boan Biotechnology Co and its competitors. This is 17% below median its historical median of 352.41. Over the past decade, Shandong Boan Biotechnology Co's Days Payable has ranged from 291.10 to 795.11. According to the industry distribution chart, Shandong Boan Biotechnology Co ranks #198 out of 700 companies in the Biotechnology industry, placing it in the top 28.3%.
Is Shandong Boan Biotechnology Co's Days Payable too high?
Shandong Boan Biotechnology Co's current Days Payable of 293.74 is 17% below median its 10-year median of 352.41. Over the past 10 years, this metric has ranged from a low of 291.10 to a high of 795.11. The Biotechnology industry median Days Payable is 112.83. Shandong Boan Biotechnology Co's value of 293.74 is 160.3% above this industry median. Based on the distribution chart, Shandong Boan Biotechnology Co ranks #198 out of 700 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Shandong Boan Biotechnology Co has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Boan Biotechnology Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shandong Boan Biotechnology Co ranks #198 out of 700 companies for Days Payable. This puts Shandong Boan Biotechnology Co in the upper half of its industry. The industry median Days Payable is 112.83. Shandong Boan Biotechnology Co's value of 293.74 is 160.3% above this benchmark. Historically, Shandong Boan Biotechnology Co's own Days Payable has ranged from 291.10 to 795.11 over the past decade. While the company's 10-year median is 352.41 vs. the industry median of 112.83, Shandong Boan Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.83, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Boan Biotechnology Co's current Days Payable of 293.74 is 160.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shandong Boan Biotechnology Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Boan Biotechnology Co's current Days Payable is 293.74, which is 17% below median its own 10-year median of 352.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Boan Biotechnology Co stock overvalued right now?
Shandong Boan Biotechnology Co (FRA:UJ9) has a current Days Payable of 293.74. The stock's GF Value™ is €1.70, compared to a current price of €0.54 — trading 68.2% below its estimated fair value. The current Days Payable is 293.74, which is 17% below median its 10-year median of 352.41 and 160.3% above the Biotechnology industry median of 112.83. Shandong Boan Biotechnology Co's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Shandong Boan Biotechnology Co (FRA:UJ9), the current Days Payable is 293.74 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Boan Biotechnology Co (FRA:UJ9) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Boan Biotechnology Co stock appears to be undervalued.
The current stock price of €0.54 is trading 68.2% below its estimated GF Value™ of €1.70.
Key valuation signals for FRA:UJ9:
Days Payable: 293.74 (17% below median its 10-year median of 352.41)
GF Value™: €1.70 vs. price of €0.54 (68.2% below fair value)
Industry Position: 160.3% above the Biotechnology median (#198 of 700)
No single metric tells the full story. See the FRA:UJ9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Boan Biotechnology Co Business Description
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.
39GF Score
Get the complete analysis for FRA:UJ9
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UJ9 has been successfully added to your 
